Company Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 07:08:53 2024-03-04 am EST 5-day change 1st Jan Change
653 DKK +0.62% Intraday chart for Zealand Pharma A/S +0.69% +74.97%

Business Summary

Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.

Number of employees: 253

Sales per Business

DKK in Million2022Weight2023Weight Delta
Peptide-based Medicines
100.0 %
104 100.0 % 343 100.0 % +229.65%

Sales per region

DKK in Million2022Weight2023Weight Delta
Germany
85.9 %
-- 294,509 85.9 % -
Denmark
12.9 %
35 33.7 % 44,185 12.9 % +126,142.86%
United States
1.2 %
69 66.3 % 4,094 1.2 % +5,833.33%

Managers

Managers TitleAgeSince
Chief Executive Officer 50 09-12-31
Director of Finance/CFO - 22-10-31
Chief Tech/Sci/R&D Officer - 20-09-03
Chief Operating Officer 52 18-02-28
Chief Tech/Sci/R&D Officer 62 22-06-01
Director/Board Member 57 -
Investor Relations Contact - -
General Counsel 56 -
Comptroller/Controller/Auditor - -
Human Resources Officer 39 19-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 66 19-04-03
Chairman 69 14-12-31
Director/Board Member 68 18-04-18
Director/Board Member 75 04-12-31
Director/Board Member 58 19-04-03
Director/Board Member 73 12-04-24
Director/Board Member 70 10-09-30
Director/Board Member 65 19-04-03
Director/Board Member 47 19-12-31
Director/Board Member 57 -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 62,508,175 58,275,554 ( 93.23 %) 373,134 ( 0.5969 %) 93.23 %

Shareholders

NameEquities%Valuation
Van Herk Investments BV
9.971 %
6,233,183 9.971 % 429 M kr
Polar Capital LLP
9.034 %
5,647,561 9.034 % 389 M kr
J.O. Hambro Capital Management Ltd.
5.004 %
3,128,162 5.004 % 215 M kr
MP Investment Management A/S
4.182 %
2,614,590 4.182 % 180 M kr
Nykredit Bank A/S (Investment Management)
1.245 %
778,494 1.245 % 54 M kr
373,134 0.5969 % 26 M kr
Fundamental Fondsmæglerselskab A/S
0.4964 %
310,340 0.4964 % 21 M kr
Amundi Asset Management SA (Investment Management)
0.4854 %
303,417 0.4854 % 21 M kr
Banque Internationale À Luxembourg SA (Denmark)
0.4387 %
274,263 0.4387 % 19 M kr
Danske Bank A/S (Investment Management)
0.4211 %
263,234 0.4211 % 18 M kr

Holdings

NameEquities%Valuation
373,134 0.60% 25,677,500 $

Company contact information

Zealand Pharma A/S

Sydmarken 11

2860, Soborg

+45 88 77 36 00

http://www.zealandpharma.com
address Zealand Pharma A/S(ZEAL)
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW